Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.fatetherapeutics.com
Fate Therapeutics, Inc. News Releases
Get the latest updates from Fate Therapeutics, Inc. News Releases directly as they happen.
Follow now 68 followers
Latest posts
Last updated 2 months ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2 months ago
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ...
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
2 months ago
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ...
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
2 months ago
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3 months ago
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4 months ago
SAN DIEGO , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
5 months ago
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile...
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
6 months ago
SAN DIEGO , Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
6 months ago
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
6 months ago
SAN DIEGO , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
6 months ago
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory...
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
7 months ago
SAN DIEGO , Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
7 months ago
SAN DIEGO , Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...